

Resource Summary Report

Generated by ASWG on Aug 9, 2026

PE/Cyanine7 anti-human CD8

RRID:AB_2044008

Type: Antibody

Proper Citation

BioLegend Cat# 344712, RRID:AB_2044008

Antibody Information

URL: http://antibodyregistry.org/AB_2044008

Proper Citation: BioLegend Cat# 344712, RRID:AB_2044008

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2044008

Vendor: BioLegend

Catalog Number: 344712

Alternative Catalog Numbers: 344750, 344711

Record Creation Time: 20250819T204646+0000

Record Last Update: 20250819T204736+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD8.

No alerts have been found for PE/Cyanine7 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Kobiyama K, et al. (2025) Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox. *EBioMedicine*, 115, 105703.

Zhou Y, et al. (2025) Glucose-1-phosphate promotes compartmentalization of glycogen with the pentose phosphate pathway in CD8+ memory T cells. *Molecular cell*, 85(13), 2535.

Schneiderova P, et al. (2025) The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation. *Cell reports*, 44(7), 115859.

Laheurte C, et al. (2025) UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. *Cell reports. Medicine*, 6(7), 102196.

Tang M, et al. (2025) Single cell immune profiling in ankylosing spondylitis reveals resistance of CD8+ T cells to immune exhaustion. *iScience*, 28(7), 112715.

Liu L, et al. (2025) Isoformic PD-1 impedes B cell activation and function in HIV-1 infection. *Cell reports*, 44(10), 116341.

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. *Immunity*, 57(9), 2232.

Bharadwaj NS, et al. (2024) Human CD4+ memory phenotype T cells use mitochondrial metabolism to generate sensitive IFN- γ responses. *iScience*, 27(5), 109775.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Zhang YC, et al. (2024) Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies. *Theranostics*, 14(16), 6249.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. *Cell reports. Medicine*, 5(3), 101448.

Imai H, et al. (2023) Peripheral T cell profiling reveals downregulated exhaustion marker and increased diversity in lymphedema post-lymphatic venous anastomosis. *iScience*, 26(6), 106822.

Swanstrom AE, et al. (2023) Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV. *EBioMedicine*, 95, 104764.

Zonozi R, et al. (2023) T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. *Science translational medicine*, 15(724), eadh4529.

Ritacco C, et al. (2023) Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. *iScience*, 26(3), 106085.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. *Med (New York, N.Y.)*, 4(5), 326.

Martínez-Sabadell A, et al. (2022) The target antigen determines the mechanism of acquired resistance to T cell-based therapies. *Cell reports*, 41(3), 111430.

Martínez-Sabadell A, et al. (2022) Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice. *STAR protocols*, 3(4), 101712.

Zheng C, et al. (2022) Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. *Cancer cell*, 40(4), 410.